Study on Application of Data Organization and Common Data Model of the Observational Medical Outcomes Partnership in US

Abstract

Abstract: Objective To provide thought and references for the promotion of ADR monitoring in China, suggestions on the secondary use of observational data for maximizing the benefit and minimizing the risk of drug use. Methods The data organization and access models of the Observational Medical Outcomes Partnership in US and the Common Data Model were studied and analyzed. Results and Conclusion The establishment and implementation of OMOP has obvious characteristics. In order to use existing multiple observational healthcare databases for active drug safety and benefit monitoring, the critical factor and the basis on the technical levels are the construction, improvement and unification of the medical information standards. The CDM design, development and evaluation can provide good thought and references for secondary use of observational data and active drug safety surveillance by establishing partnership and using a variety of data sources in China.

Key words: observational data, secondary use, data model, active surveillance

CLC Number:

WANG Ling. Study on Application of Data Organization and Common Data Model of the Observational Medical Outcomes Partnership in US[J]. Chinese Journal of Pharmacovigilance, 2015, 12(6): 341-346.

References

[1] EMA.Road map to 2015[EB/OL].（2010-12-16）[2014-12-23].www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500101373.
[2] FDA.Food and Drug Administration Amendments Act of 2007[EB/OL].（2007-09-27）[2014-12-23].http://www.fda.gov/Regulat-oryInformation/Legislation/FederalFoodDrugandCosmeticActFD-CAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAALaw/default.htm.
[3] FDA.FDA's Sentinel Initiative-Background[EB/OL].（2010-01-19）[2014-12-23]. http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm.
[4] 王玲.欧美药物警戒中电子化医疗保健数据的应用研究[J].中国药物警戒，2015，12（3）：156-159.
[5] FDA.FDAAA Implementation-Highlights One Year After Enactment[EB/OL].（2009-04-27）[2014-12-23].http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmetic-ActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/ucm083161.htm.
[6] OMOP.About Us[EB/OL].[2014-12-23].http://omop.org/node/22.
[7] REAGAN-UDALL FOUNDATION.Innovationin Medical Evidence Development andSurveillance (IMEDS) Program[EB/OL].[2014-12-23].http://www.reaganudall.org/our-work/safety-and-better-
evidence/imeds-program/.
[8] Stang P E, Ryan P B, Racoosin J A, et al.Advancing the Science for Active Surveillance：Rationale and Design for the Observational Medical Outcomes Partnership[J].Annals of Internal Medicine，2010，153（9）：600-606.
[9] Scarnecchia T.OMOP Overview and Insights[C].Washington,DC-2010:46th DIA Annual Meeting.
[10] Overhage J M, Ryan P B, Reich C G, et al, et al.Validation of a common data model for active safety surveillance research[J].J Am Med Inform Assoc，2012，19（1）:54-60.
[11] FNIH.OMOP Common Data Model Specifications[EB/OL].（2012-04）[2014-12-23]. http://archive-omop.fnih.org/CDMvocabV4.
[12] Zhou X F, Murugesan S, Bhullar H, et al. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance[J]. Drug Saf，2013， 36（2）:119-134.
[13] Matcho A, Ryan P, Fife D, et al. Fidelity Assessment of a Clinical Practice Research Datalink Conversion to the OMOP Common Data Model[J]. Drug Saf，2014， 37（11）:945-959.
[14] 王玲.基于医院信息系统开展药品不良反应监测研究[J].中国药物警戒，2015，12（4）：229-231.

[1]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[2]	ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
[3]	WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
[4]	LIU Zhike, ZHAN Siyan. Progress in applications of self-controlled designs in association study of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
[5]	SUN Yixin, LIU Zhike, ZHAN Siyan. Scoping review of near real-time surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
[6]	HOU Yongfang, SONG Haibo, LIU Hongliang, LI Xilin. Practice and Discussion on Active Surveillance by China Hospital Pharmacovigilance System [J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 212-214.
[7]	WANG Meng, GUO Xiaojing, YE Xiaofei, XU Jinfang, HU Fangyuan, HE Jia. Application of Bayesian Instrumental Variable in Active Surveillance Data of Adverse Drug Reactions:a Simulation Study [J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 139-143.
[8]	GUO Xiaojing, WANG Meng, GUO Wei, YE Xiaofei, ZHU Tiantian, HE Jia. Status and Challenges of Controlling Confounding Factors in Active Surveillance of Adverse Drug Reactions [J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 595-599.
[9]	CAI Ting, YANG Yu, WANG Ya-li, DONG Duo, ZHAN Si-yan. Review and Analysis of Active Post-marketing Surveillance Modes for Vaccine Safety [J]. Chinese Journal of Pharmacovigilance, 2017, 14(8): 464-469.
[10]	HOU Yong-fang, SHEN Lu, LIU Wei, SONG Hai-bo, LIU Cui-li, WANG Dan, LI Xin-ling. Medical Product Active Surveillance System in America and Its Revelation [J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 32-35.
[11]	SHEN Lu, LIU Wei, HOU Yong-fang, GUO Xue, PENG Li-li, KONG Fan-yao, LI Xin-ling. Ideas on the Project of Drug Safety Data Partner Cooperation in China [J]. Chinese Journal of Pharmacovigilance, 2016, 13(12): 737-739.
[12]	ZHANG Qian-ting, WANG Ya-li, QU Yi. Discussion on Vaccine Active Surveillance in China [J]. Chinese Journal of Pharmacovigilance, 2016, 13(11): 673-675.
[13]	WANG Dan. Active Surveillance of Adverse Drug Reaction and Its Development Trend [J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 600-602.
[14]	SHEN Lu. Analysis of the Law and Policy Framework for Use of Electronic Health Data in FDA's Sentinel Initiative [J]. Chinese Journal of Pharmacovigilance, 2015, 12(1): 30-33.
[15]	CHEN Chao,GUO Dai-hong, XUE Wan-guo, LIU Dong-jie, LIU Gui-yang, ZHU Man . Development of Alarming System to Actively Monitor and Assess the Adverse Drug Events in Hospitalized Patients [J]. Chinese Journal of Pharmacovigilance, 2013, 10(7): 411-414.